Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 4Withdrawn 2Recruiting 2Not yet recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 437Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 174Colorectal Neoplasms 156Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 130Lymphoma 127Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Brain Neoplasms 101Recurrence 100Head and Neck Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 96Leukemia 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 74Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × CRC × Clear all
NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

NCT03337776 2021-08-05

Effect of WhatsApp Messenger on Uptake of CRC Screening Study

Chinese University of Hong Kong

Phase NA Withdrawn

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡